The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as a panel of government advisers on Tuesday endorsed kid-size doses of Pfizer's shots for 5- to 11-year-olds.
A Food and Drug Administration advisory panel voted unanimously, with one abstention, that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks — including a heart-related side effect that's been very rare in teens and young adults despite their use of a much higher shot dose.
While children are at lower risk of severe COVID-19 than older people, ultimately many panelists decided it's important to give parents the choice to protect their youngsters — especially those at high risk of illness or who live in places where other precautions, like masks in schools, aren't being used.
The virus is “not going away. We have to find a way to live with it and I think the vaccines give us a way to do that,” said FDA adviser Jeannette Lee of the University of Arkansas.
“I do think it’s a relatively close call,” said adviser Dr. Eric Rubin of Harvard University. “It’s really going to be a question of what the prevailing conditions are but we’re never going to learn about how safe this vaccine is unless we start giving it.”
The FDA isn’t bound by the panel’s recommendation and is expected to make its own decision within days.
If the FDA authorizes the kid-size doses, there’s still another step: Next week, the Centers for Disease Control and Prevention will have to decide whether to recommend the shots and which youngsters should get them.
Full-strength shots made by Pfizer and its partner BioNTech already are recommended for everyone 12 and older but pediatricians and many parents are clamoring for protection for younger children. The extra-contagious delta variant has caused an alarming rise in pediatric infections -- and families are frustrated with school quarantines and having to say no to sleepovers and other rites of childhood to keep the virus at bay.
States are getting ready to roll out shots for little arms -- in special orange-capped vials to distinguish them from adult vaccine -- as soon as the government gives the OK. More than 25,000 pediatricians and other primary care providers have signed up so far to offer vaccination.
While there is less COVID-19 among 5- to 11-year-olds, they still have faced substantial illness -- including over 8,300 hospitalizations reported, about a third requiring intensive care, and nearly 100 deaths.
A study of elementary schoolchildren found the Pfizer shots are nearly 91% effective at preventing symptomatic infection -- even though the youngsters received just a third of the dose given to teens and adults.
Pfizer’s study tracked 2,268 children ages 5 to 11 who got two shots three weeks apart of either a placebo or the kid dose. Vaccinated youngsters developed levels of virus-fighting antibodies just as strong as teens and young adults who got the full-strength shots.
The kid dosage also proved safe, with similar or fewer temporary side effects — such as sore arms, fever or achiness — that teens experience. At FDA’s request, Pfizer more recently enrolled another 2,300 youngsters into the study, and preliminary safety data has shown no red flags.
The study isn’t large enough to detect any extremely rare side effects, such as the heart inflammation that occasionally occurs after the second dose, mostly in young men and teen boys.
Statistical models developed by FDA scientists showed that in most scenarios of the continuing pandemic, the vaccine would prevent far more COVID-19 hospitalizations in this age group than would potentially be caused by that very rare side effect, heart inflammation, that's the big unknown.
But with cases falling across the U.S., the FDA panel had to consider whether the pandemic might recede so much that more children could face side effects from the vaccine than would be protected from COVID-19.
“If the trends continue the way they are going then the emergency for children is not what we might think it might be,” said Dr. James Hildreth of Meharry Medical College.
Moderna also is studying its vaccine in young children, and Pfizer has additional studies underway in those younger than 5.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Updated on October 26, 2021, at 5:21 p.m. ET with additional details.
Stocks closed lower Monday as investors continued to price in COVID-19 omicron variant fears. Reopening stocks like airlines, financial companies, restaurants and hotels, and more, dragged on the major indexes as businesses and events took a pause over the weekend amid rising case numbers in metropolitan areas. This comes a week after the Federal Reserve announced it plans to speed up its asset tapering timeline in January and institute three rate hikes next year. Is that plan aging well? Robert Conzo, CEO of The Wealth Alliance, joins Cheddar News' Closing Bell to discuss market movement, how stocks could close out the year, what the Fed could do in 2022, and more.
After a vote in one Buffalo, New York-area Starbucks created the first workers union in the coffee chain's history, the company has announced that it is ready to negotiate in good faith with the new bargaining unit. But a tense process where labor organizers leveled accusations of anti-union activity at the coffee giant may make that difficult. Cortlin Harrison, a barista at the unionized store, spoke to Cheddar about making a deal. "We can move past all the dirty tricks, the union-busting, the captive audience meetings," he said. "I'm ready to go to the table, and my fellow baristas are ready to go to the table, and just move forward."
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
American Express and Nova Credit have partnered the credit passport program aimed at expanding access to credit for immigrants from the Dominican Republic, Nigeria, Kenya, and Brazil. Misha Esipov, co-founder and CEO of Nova Credit, joined Cheddar's Ken Buffa to talk about the program's benefits for immigrants who have to start over in the U.S. and are looking to establish a credit history. "If you were a good borrower in your home country — and you can prove you were a borrower in your home country — when you first arrive here, you can use that information to continue to be a good borrower," he said of the service.
Despite the rising cost of a home in the U.S., sales rose 1.9 percent in November, and according to Zillow, prices are expected to climb even higher in 2022. M. Ryan Gorman, president and CEO of Coldwell Banker Real Estate, told Cheddar's "Closing Bell" that while median prices are high, demand for a new home is just as high, particularly in "tax and weather favorable" destinations like Florida, Tennessee, and Texas. Gorman also said he sees buyer demand remaining high next year even if interest rates rise somewhat, noting that the already tight housing inventory is expected to slim down even more and foreign purchasers return to the market. "As we get past the holidays and those foreign buyers are able to come back and actually acquire homes and go shopping, I think that may be a bigger driver of some of that increase in buyer demand," he said.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
A new series is looking to advance Black founders who have disruptive ideas and companies. 'Bet on Black' is a new series that allows black entrepreneurs to pitch their businesses in the hopes of securing $200,000 in funding. Revolt TV and Target teamed up to create the show. Detavio Samuels, CEO of Revolt, joins Cheddar News to discuss.
Bitcoin's rise to the mainstream has been a wild ride this year. The cryptocurrency is trading a little under $49,000 Wednesday morning and is set to finish the year sharply higher than where it began earlier this year. Ether prices also soared this year, rising from $730 per coin to nearly $4,000. Ben Armstrong, founder of Bitboy Crypto, joins us to discuss what's in store for crypto in 2022.
